Borealisbio
A contract Chemist at Borealis Biosciences supports complex chemical workflows in a research environment, ensuring accurate compound registration, improving inventory systems, and enabling scalable solid-phase chemistry capabilities.
Borealis Biosciences is a biotech company developing RNA medicines that selectively target kidney cells to treat chronic kidney diseases with large unmet need. Founded by an experienced drug‑discovery team (building on the Chinook Therapeutics group acquired by Novartis), Borealis combines targeted RNA delivery, translational systems biology, data science, chemistry, DMPK and pharmacology to pursue validated causal targets not addressable by traditional small molecules or biologics. Backed by Versant Ventures, Novartis and Westlake Bio, the company launched with a $150M Series A and is headquartered in Vancouver, BC.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Borealisbio.
Research Fellow in Organic Chemistry
Nanyang Technological University
Senior Scientist - CMC
Empirico
Research Fellow in Organic Chemistry
Nanyang Technological University
Scientist – Peptide Chemistry
AstraZeneca
Associate Scientist, Resynthesis
Terray Therapeutics
Sr./Staff Scientist, Peptide/Nucleic Acid Chemistry
Fapon Biotech